ArticleInternational journal of surgery (London, England)2026
Intrinsic capacity, genetic susceptibility, and the risks of metabolic dysfunction-associated steatotic liver disease and cirrhosis.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization has introduced a new functional aging framework centered on intrinsic capacity (IC). This study aimed to evaluate the relationship between IC and the risk of incident metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis, and to assess the potential modifying effect of genetic susceptibility.
methodsWe included 393 355 participants without prior liver disease from the UK Biobank. A comprehensive IC deficit score was constructed using seven indicators across four IC domains. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).
resultsOver a median follow-up of 14 years, 5279 MASLD and 1782 cirrhosis cases were identified. Compared with individuals with an IC deficit score of 0, those with a score of 4 or more had a significantly higher risk of MASLD (HR: 1.84; 95% CI: 1.63-2.08) and cirrhosis (HR: 2.17; 95% CI: 1.77-2.65). Participants with both a high polygenic risk score (PRS) and an IC deficit score of 4+ had the highest risk of MASLD (HR: 2.78; 95% CI: 2.29-3.36) and cirrhosis (HR: 3.30; 95% CI: 2.44-4.46), compared with those with low PRS and an IC score of 0. Moreover, individuals with an IC deficit score of 3+ had elevated risks of MASLD (HR: 1.23; 95% CI: 1.08-1.40) and nonalcoholic steatohepatitis (HR: 1.37; 95% CI: 1.08-1.72), defined by liver proton density fat fraction >5% or iron-corrected T1 ≥ 800 ms. A greater rate of IC decline over time was associated with increased risks of both MASLD and cirrhosis.
conclusionsLower ICs are independently associated with increased risks of MASLD and cirrhosis, regardless of genetic susceptibility. These findings suggest that routine monitoring and early intervention targeting IC may offer a novel strategy to prevent chronic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.